Levo-dihydroxyphenylalanine--Parkinson's disease and manganese poisoning.
作者信息
Goldman M E
出版信息
IMS Ind Med Surg. 1972 Apr;41(4):12-5.
PMID:4502399
Abstract
摘要
相似文献
1
Levo-dihydroxyphenylalanine--Parkinson's disease and manganese poisoning.左旋二羟基苯丙氨酸——帕金森病与锰中毒。
IMS Ind Med Surg. 1972 Apr;41(4):12-5.
2
Metabolic modification of some neurologic disorders.某些神经系统疾病的代谢改变
JAMA. 1969 Nov 17;210(7):1255-62.
3
[Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].[左旋多巴与脱羧酶抑制剂（Ro 4-4602）治疗帕金森综合征。71例患者的病程]
Schweiz Med Wochenschr. 1972 Jan 22;102(3):88-94.
4
The pharmacology of extrapyramidal movement disorders.锥体外系运动障碍的药理学
Monogr Neural Sci. 1973;2:1-136.
5
Metabolic modification of Parkinson's disease and of chronic manganese poisoning.帕金森病与慢性锰中毒的代谢改变。
Annu Rev Med. 1971;22:305-26. doi: 10.1146/annurev.me.22.020171.001513.
6
The biochemistry of catecholamines in relation to Parkinson's disease.与帕金森病相关的儿茶酚胺生物化学
Aust N Z J Med. 1971 May;1:Suppl 1:14-8. doi: 10.1111/j.1445-5994.1971.tb02560.x.
7
L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
Can Psychiatr Assoc J. 1972 Apr;17(2):123-31. doi: 10.1177/070674377201700207.
8
[The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].[左旋多巴在帕金森病中的治疗应用。生化、药理及临床考量]
Recenti Prog Med. 1970 Feb;48(2):97-124.
9
[Recent advances and pharmacological basis of the medical treatment of Parkinson's syndrome].[帕金森综合征药物治疗的最新进展及药理学基础]
Shinkei Kenkyu No Shimpo. 1971;15(4):992-1002.
引用本文的文献
1
Strategy for the assessment of neurobehavioral consequences of environmental factors.环境因素神经行为后果评估策略。
Environ Health Perspect. 1978 Oct;26:287-99. doi: 10.1289/ehp.7826287.
Zotero 插件